Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urinary Tract Biopsy Correlates Urothelial Carcinoma Diagnosis

By LabMedica International staff writers
Posted on 28 Sep 2017
Urothelial carcinoma (UCC), also known as transitional cell carcinoma (TCC) is a type of cancer that typically occurs in the urinary system. More...
It is the most common type of bladder cancer and cancer of the ureter.

UCC is the second most common type of kidney cancer, but accounts for only five to 10% of all primary renal malignant tumors. UCC arises from the transitional epithelium, a tissue lining the inner surface of these hollow organs. Transitional cell carcinoma (TCC) accounts for more than 95% of urothelial tumors of the upper urinary tract.

Scientists at the University of Chicago (Chicago, IL, USA) searched their Department of Pathology archive for all cases of upper urothelial tract biopsies and washings between the years 2005 and 2015 that had nephroureterectomy for urothelial carcinoma. In all, 126 patients met the inclusion criteria. They considered cytology diagnoses of either urothelial cancer or “suspicious for urothelial cancer” to be positive. They compared the concordance between combined biopsy and washing, and then compared biopsy and washing diagnoses with the presence of carcinoma on resection.

The team found that from the 126 patients who had resection, only 72 patients had prior diagnostic material. Of those, 33 (26%) had combined biopsy and washing, 26 (21%) had biopsy only, and 13 (10%) had washing only. Among the patients who had had both procedures, 15 (45%) of the diagnoses were concordant as indicated by positive biopsy and cytology, and the final resection specimen revealed urothelial carcinoma. One patient, who was considered concordant, had negative results for both procedures but had urothelial carcinoma on resection.

The scientists found that among the 17 discordant combined biopsy and cytology cases, 11 had positive biopsy with negative washing, four had negative biopsy with positive washing and for two cases, neither biopsy nor washing was diagnostic. Among the 11 positive biopsies with negative washing, five were low-grade papillary urothelial cancer, four were high-grade papillary urothelial cancer, one was urothelial cancer in situ, and one was high-grade urothelial cancer suspicious for invasion.

Providers often obtain biopsies and cytology washings of the upper urinary tract to help them diagnose urothelial cancer, but may have only one procedure performed. Shiraz Fidai, MD, and Tatjana Antic, MD, co-authors of the study, said, “Overall, based on our data, both biopsies and washings of the upper tract (83% for biopsies and 59% for washings) are appropriate in diagnosing urothelial cancer. However, biopsies are more suitable for diagnosing low-grade papillary urothelial cancer when compared with cytology. Size and multifocality of the urothelial cancer of the upper urinary tract plays a significant role in obtaining an adequate specimen for either diagnosis or grading.” The study was presented at the Annual Meeting of the American Society for Clinical Pathology (ASCP), held September 6-8, 2017, in Chicago, IL, USA.

Related Links:
University of Chicago


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.